Recon: AbbVie purchases Immunogen for $10 billion to boost cancer portfolio; Cigna and Humana merger talks underway

• AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion (STAT)
• Cigna, Humana in Talks for Blockbuster Merger (Wall Street Journal)
• Vivos receives FDA 510(k) clearance for oral devices to treat severe sleep apnea (MedTech Dive)
• GE HealthCare gets 510(k) clearance for algorithm to detect collapsed lungs (MedTech Dive)
• ‘Fire, smoke, burns’: FDA warns about new safety risks for Philips CPAP machines (MedTech Dive)

• With latest tranche, U.K. Biobank has genome sequences from 500,000 people available for research (STAT)
• Turkey launches investigation into 19 pharma companies (Reuters)
• GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year (Reuters)
• Philips investor Exor: company's problems are "solvable" (Reuters)
• India's Tata Technologies valued at $6.4 bln after smashing debut (Reuters)
• Medtech Industry Weighs In On EMA’s AI Regulation Proposals (MedTech Insight)
• Latest Notified Body Designated Under the EU’s MDR Is A Software Specialist (MedTech Insight)
• EU Member States Call For Action Over High-Risk IVDs And Eudamed Medical Device Database (MedTech Insight)

• Do GLP-1s have a future treating alcoholism? (STAT)
• Cell manufacturing company raises $19M Series A to increase capacity, staff numbers (Endpoints)
• Cybin gears up for registrational trial of psilocybin analog in major depression after PhII success (Endpoints)
• Charles River works on rare disease gene therapy; Emergent gets $75M for anthrax vaccine; EuroAPI hires new COO (Endpoints)
• Flagship aims to raise $3B; Phenomic inks another pharma deal; Oncovita gets €8M for cancer vaccine (Endpoints)
• CRO Fortrea 'disputes the accuracy' of Acelyrin's claims about immunology drug trial conduct (Endpoints)
• Xenon offers $300M in shares after touting path ahead for MDD program despite PhII miss (Endpoints)
• Orna Therapeutics trims staff in ‘defensive reduction’ despite large financing hauls (Endpoints)
• Health tech stands out as a top area for early-stage VC funding in Q3 (Endpoints)
• Neuro startup stock craters after PhIII study marred with ‘significant deviation’ from trial protocol (Endpoints)
• No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype (MedTech Insight)

• Diagnostic tests for rare conditions present a mathematical conundrum (STAT)
• Boehringer Ingelheim and IBM team up to make antibodies with generative AI (Endpoints)
• J&J heats up LAA closure competition with $400M Laminar buy (MedTech Dive)
• 3 medtech spinoffs that reshaped the industry in 2023, and what to expect next (MedTech Dive)
• Cleveland Clinic, Canon to establish medical imaging research center (MedTech Dive)

• The surprising environmental cost of rapid testing, mosquito nets, and other lifesaving health products (STAT)
• How artificial intelligence could make pregnancy discrimination in employment more common (STAT)